NASDAQ:ABVX Abivax Q2 2026 Earnings Report $105.22 -1.77 (-1.65%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPSN/AConsensus EPS -$0.92Beat/MissN/AOne Year Ago EPSN/AAbivax Revenue ResultsActual RevenueN/AExpected Revenue$0.80 millionBeat/MissN/AYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ2 2026Date9/21/2026TimeAfter Market ClosesConference Call DateMonday, September 21, 2026Conference Call Time11:40AM ETConference Call ResourcesEarnings HistoryCompany Profile Abivax Earnings HeadlinesBank of America drops back below 5% in AbivaxSeptember 14, 2026 | marketscreener.comMAbivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallSeptember 14, 2026 | benzinga.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 18 at 1:00 AM | American Alternative (Ad)Abivax Announces Positive Pre-NDA Interaction with the FDA for ObefazimodJuly 30, 2026 | markets.businessinsider.comABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?July 26, 2026 | finance.yahoo.comAbivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D DealJuly 25, 2026 | finance.yahoo.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxAbivax (NASDAQ:ABVX) is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways. Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease. The company is conducting late-stage clinical development to assess the product’s safety and efficacy in patients with moderate-to-severe ulcerative colitis. Founded in 2013, Abivax initially pursued programs in infectious diseases and immune-related conditions before concentrating on inflammatory bowel disease. The company conducts research and clinical development activities internationally and is listed on the Nasdaq Capital Market under the symbol ABVX and on Euronext Paris.View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
